Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0779
    -0.0014 (-0.13%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2619
    -0.0003 (-0.02%)
     
  • USD/JPY

    151.4000
    +0.0280 (+0.02%)
     
  • Bitcoin USD

    70,435.16
    +194.55 (+0.28%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

IMPORTANT SERES THERAPEUTICS, INC. SHAREHOLDER REMINDER: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors that a Securities Class Action Lawsuit has been Filed on behalf of Shareholders of Seres Therapeutics, Inc.

Lead Plaintiff Deadline is November 28, 2016

NEW YORK, NY / ACCESSWIRE / November 1, 2016 / Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has been filed against Seres Therapeutics, Inc. ("Seres" or the "Company") (MCRB) in the United States District Court for the District of Massachusetts. The class action is on behalf of a class consisting of all persons or entities who purchased Seres securities between June 25, 2015 through July 29, 2016, inclusive (the "Class Period").

Shareholders who have incurred losses in Seres Therapeutics, Inc. are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774. You may also review the filed complaint and obtain additional information concerning the action on our website, www.whafh.com.

If you purchased securities of Seres you may, no later than November 28, 2016, request that the Court appoint you lead plaintiff of the proposed class.

The filed Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that Defendants were aware that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint of CDI recurrence as compared to placebo. Despite having knowledge that the parallel open-label study of SER-109 was struggling with enrollment rates, a clear indication that SER-109 was not performing well in its Phase 2 clinical trial, Defendants continued to tout SER-109's potential and efficacy. In addition, management was aware that the Company had made formulation changes to the Phase 2 clinical trial, which could affect the clinical cure rate of SER-109.

According to the Complaint, on July 29, 2016, the Company issues a press release announcing the result of the Phase 2 clinical trial of SER-109 administered as a single oral dose for the treatment of recurrent CDI did not achieve its primary endpoint when compared to a placebo. In fact, SER-109 failed to prove that it was even marginally more effective than the placebo.

Following this disappointing and unexpected announcement, the price of Seres common stock declined from a closing price of $35.77 on July 28, 2016 to close at $9.73 per share on August 1, 2016, losing more than 70% of its value.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com.

## Follow the Firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: gstone@whafh.com, donovan@whafh.com or classmember@whafh.com
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

SOURCE: Wolf Haldenstein Adler Freeman & Herz LLP

Advertisement